Titan Pharmaceutical’s (NASDAQ:TTNP) Probuphine six-month implant of sublingual buprenorphine continues to attract widespread media attention for its ability to treat addiction to opioids. Independent TV station, WHDT...
Ocular Therapeutix (NASDAQ:OCUL) has entered into a strategic collaboration, option and license agreement with Regeneron Pharmaceuticals (NASDAQ:REGN) to develop a sustained release formulation of the vascular...
The U.S. Patent and Trademark Office has issued a patent to Mateon Therapeutics (NASDAQ:MATN) and Baylor University that covers compounds which modulate cathepsin activity, particularly cathepsin L or cathepsin K, and...
Leerink reiterated its “outperform” rating on Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP) after the company reported additional positive data for its voclosporin drug candidate in patients with active lupus nephritis...
Results of Mesoblast’s (NASDAQ:MESO; ASX:MSB) Phase 2 trial of its allogeneic mesenchymal precursor cell (MPC) product candidate, MPC-300-IV, in patients with diabetic kidney disease have been published in the current...
Profound Medical (TSX-V:PRN) has received Frost & Sullivan’s 2016 European Prostate Ablation Systems New Product Innovation Award for its TULSA-PRO system. TULSA-PRO, which received CE Mark approval in April 2016...
Dipexium Pharmaceuticals (NASDAQ:DPRX) has been granted small and medium enterprise (SME) designation by the European Medicines Agency (EMA). The company recently completed its pivotal Phase 3 clinical trials...
Cellectar Biosciences (NASDAQ:CLRB) reported positive data from the second cohort of patients enrolled in its orphan-drug designated Phase 1 study of CLR 131 in patients with relapsed or refractory multiple myeloma...
Aurinia Pharmaceuticals’ (NASDAQ:AUPH; TSX:AUP) voclosporin achieved its primary endpoint of complete remission (CR) at 24 weeks in a Phase 2b trial. In addition, when both doses of voclosporin were added to the current...
Galectin Therapeutics (NASDAQ:GALT) has completed enrollment one month early in its Phase 2b trial (NASH-CX) with 162 subjects with nonalcoholic steatohepatitis (NASH). The Phase 2b study is testing the company’s GR-MD...
USA Today has carried a profile of Sarah Wilson, wife and mother of four, who became addicted to opioid pain medications after she suffered severe injuries from being hit by an intoxicated driver about eight-years-ago...
Dresner Partners has opened a new office in Fort Lauderdale, FL to be headed by Mitchell Stern, managing director and head of Dresner Partners’ healthcare practice. Mr. Stern will also continue to spend a portion of...
The FDA has granted orphan drug designation to closely-held Soricimed Biopharma’s peptide, SOR-C13, for the treatment of pancreatic cancer, following a similar designation for ovarian cancer In a statement, Paul Gunn...
US Oncology Research will participate in Mateon Therapeutics’ (NASDAQ:MATN) FOCUS clinical trial in platinum-resistant ovarian cancer. In a statement, Dr. William Schwieterman, president and CEO of Mateon, said US...
Australia-based Global Kinetics has received 510(k) marketing clearance from the FDA for its next generation, wrist-worn Parkinson’s KinetiGraph (PKG) System. The new PKG technology enables a shift to “anywhere...
A new study of Antibe Therapeutics’ (OTCQB:ATBPF; TSX-V:ATE) ATB-346 drug candidate has shown promising results in the chemoprevention and treatment of melanoma in mice. The article was published online in the September...
The first patient has been treated in Profound Medical’s (TSX-V:PRN) TACT pivotal trial at Vanderbilt University Medical Center in Nashville, TN. TACT is a prospective, single-arm pivotal clinical study of 110 patients...
The U.S. Court of Appeals for the Federal Circuit upheld a Virginia federal jury award to LifeNet Health of $34.7-million in damages for LifeCell’s infringement of a LifeNet patent related to improving the...
TearLab (NASDAQ:TEAR; TSX:TLB) has received a letter from the Nasdaq listing qualifications staff, indicating that the company failed to regain compliance with the $1 minimum bid price requirement for continued listing...
M Pharmaceutical (OTCQB:MPHMF; CSE:MQ) announced findings from the third of three proprietary pilot studies related to the recently acquired Chelatexx technology, or the company’s C-103 project. The third study...
In a corporate update, Vital Therapies (NASDAQ:VTL) reported that 14 subjects have been enrolled at sites in the U.S. and EU in VTL-308, the company’s Phase 3 trial, designed to evaluate the ELAD System in...
Closely-held AmorChem has spun out Mperia Therapeutics, a start-up company focusing on a novel immunotherapy approach based on CD36 cell receptor drug-ligands. All rights to the CD36 technology initially held by...